Our Story
The Hepatitis Foundation of New Zealand has completed many major screening, vaccination and research programmes in New Zealand, the Pacific Islands and Vietnam during its 30-year history.
In 1984, the newly established foundation implemented the Kawerau Seroprevalence Study. It tested 93 percent of Kawerau’s population for hepatitis B. The results showed the virus was highly endemic.
Nine years later, as a result of the foundation’s work, New Zealand was the first sovereign nation to introduce universal hepatitis B vaccination for all children.
From 1999-2002 the largest national hepatitis B screening programme ever conducted took place in New Zealand. A total of 177,292 New Zealanders were screened, with 11,936 people with chronic hepatitis B identified.
In the early 2000s the foundation launched its free national long-term monitoring programme. This continues today, successfully following up and monitoring about 25,000 people with chronic hepatitis B.